600332.SH
白云山
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 20.11
−3.83%Year over year
Reported trailing growth
- Revenue
- +5.3%
- EBITDA
- —
- EBIT
- +6.9%
- EPS
- +9.2%
- Free cash flow
- -87.3%
- Operating cash flow
- -46.1%
Forward estimates
Based on analyst estimates
- Revenue
- -75.5%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +3.1%
- EBITDA
- -8.2%
- EBIT
- -10.6%
- Net income
- -9.1%
- EPS
- -9.1%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026